Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) – Investment analysts at Cormark boosted their FY2017 EPS estimates for Cipher Pharmaceuticals in a research note issued to investors on Monday. Cormark analyst D. Novak now anticipates that the company will earn $0.49 per share for the year, up from their prior estimate of $0.47.

ILLEGAL ACTIVITY NOTICE: “Research Analysts Set Expectations for Cipher Pharmaceuticals Inc’s FY2017 Earnings (CPH)” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at

A number of other equities research analysts have also issued reports on CPH. TD Securities increased their target price on shares of Cipher Pharmaceuticals from C$5.50 to C$6.50 in a report on Monday, August 14th. Bloom Burton lowered shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 14th.

Shares of Cipher Pharmaceuticals (CPH) opened at C$4.73 on Tuesday. Cipher Pharmaceuticals has a fifty-two week low of C$3.50 and a fifty-two week high of C$5.75.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.